{"changeSha256":"c078410393655343be5a0991e75524b1e0aa0966d0b9bcc8aa99f0a1d06952a4","changedAt":"2026-07-29","changedFields":[{"after":"FDA compounding safety review; final determination pending","before":"FDA identity record only; approval status not established","field":"Status"},{"after":"safety-review","before":"identity-only","field":"Status classification"},{"after":"Safety records","before":"Identity records","field":"Topic"},{"after":"A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.","before":"A research-peptide name that FDA's substance registry maps to a thymosin beta-4 fragment.","field":"Profile summary"},{"after":"FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.","before":"FDA's substance registry identifies TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4 and explicitly states that a UNII record does not imply regulatory review or approval.","field":"Evidence note"},{"after":"fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026","before":"fda-tb-500-identity","field":"Cited source records"},{"after":"U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]","before":"U.S. Food and Drug Administration [sources: fda-tb-500-identity]","field":"Named organizations"},{"after":"name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing, fda-pcac-peptide-meeting-2026; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026","before":"name: fda-tb-500-identity; aliases: fda-tb-500-identity; category: fda-tb-500-identity; status: fda-tb-500-identity; summary: fda-tb-500-identity; evidenceNote: fda-tb-500-identity","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/tb-500/versions/2/","version":2},"id":"profile:tb-500:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.","peptideSlugs":["tb-500"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/tb-500/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-tb-500-briefing","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA briefing document for TB-500","url":"https://www.fda.gov/media/193349/download","verifiedAt":"2026-07-29"},{"id":"fda-pcac-peptide-meeting-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting","url":"https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026","verifiedAt":"2026-07-29"}],"subject":{"slug":"tb-500","type":"profile"}}